COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

  • External Link
Christopher Larson, Bryan Oronsky, Sharad Goyal, Carolyn Ray, Farah Hedjran, Terese C. Hammond, Santosh Kesari, Scott Caroen, Michelle Lybeck, Vaughn E. Dobalian, Arnold Oronsky, and Tony Reid

Biochim Biophys Acta Rev Cancer. 2020 Aug 20.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious zoonotic pathogen that has exacted heavy public health, social and economic tolls. In February 2020, the World Health Organization acronymed the disease caused by SARS-CoV-2 as COVID-19, for coronavirus disease 2019. The number of confirmed COVID-19 infections, which has been detected in at least 103 countries, has reached 1,970,225 worldwide as of April 14, 2020 with 124,544 deaths, according to the U.S. Centers for Disease Control and Prevention (CDC).

Many cases of COVID-19 resolve quickly. However, the disease, which, like other respiratory pathogens that cause common cold symptoms is believed to be transmitted through respiratory droplets. Infection with COVID-19 can also lead to significant morbidity and death; this is particularly the case for cancer patients. Moreover, because the signs and symptoms of COVID-19 are easily misattributed to the sequelae of cancer itself, such as pulmonary embolism, or its treatment, such as nausea and diarrhea, diagnosis may be delayed or missed. Potential COVID-19 rule out criteria, based on the Wells' criteria for pulmonary embolism, another protean disease entity, are provided as a decision-making aid. This review summarizes the current understanding of the transmission, clinical presentation, diagnosis and differential diagnosis, pathogenesis, rationale to treat the cancer or not, treatment and prevention of COVID-19 with an emphasis on implications in cancer.
Clinical Trial

Expanded Access to Convalescent Plasma for Treatment of Patients with COVID-19

Saint John’s Health Center is one Providence St. Joseph Health site collaborating with Mayo Clinic for the FDA approved COVID-19 convalescent plasma patient access program.

This expanded access treatment protocol will provide convalescent plasma to patients in need. Historically,…